Hyundai Engineering Co. will build a 400 billion won plant in Dangjin that uses plastic wastes in producing high-purity clean hydrogen.
The plant will process 100,000 tons of plastic wastes annually to produce 22,000 tons of high-purity clean hydrogen through pyrolysis and gasification.
The hydrogen produced will be used as a raw material for hydrogen-electric vehicles, hydrogen-LNG co-firing power generation, hydrogen fuel cell power generation.
The plant is part of efforts to diversify its business towards eco-friendly energy production.
The company, a plant engineering affiliate of Hyundai Motor Group, expects to break ground in the first half of next year.
Full-scale commercial production is expected to begin in 2024.
Hyundai Engineering will collect and use most of the carbon dioxide generated during the process through a Metal-CO2 system that is now being tested at Hyundai Steel Co.’s Incheon plant.


European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens
Lake beds are rich environmental records — studying them reveals much about a place’s history
Tabletop particle accelerator could transform medicine and materials science
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low
Burkina Faso and Mali’s fabulous flora: new plant life record released
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Drug pollution in water is making salmon take more risks – new research
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 



